Company profile

Incorporated in
Fiscal year end
IRS number


24 Feb 20
5 Apr 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Revenue 7.95B 6.01B 6.27B 5.92B
Net income -1.06B 1.35B 1.43B 1.71B
Diluted EPS -0.55 0.83 0.87 1.04
Net profit margin -13.29% 22.52% 22.83% 28.89%
Net change in cash -18.14B 2.09B 21.07B 424M
Cash on hand 12.35B 30.49B 28.4B 7.34B
Cost of revenue 2.43B 1.81B 1.99B 1.84B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 26.15B 22.56B 20.78B 19.43B
Net income 3.44B 4.92B 1.01B 4.46B
Diluted EPS 2.01 3.01 0.61 2.65
Net profit margin 13.15% 21.81% 4.85% 22.94%
Net change in cash 5.44B 1.49B 1.18B 1.85B
Cash on hand 12.35B 6.91B 5.42B 4.24B
Cost of revenue 8.08B 6.47B 6.01B 4.97B

Financial data from company earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
1 Apr 20 Elizabeth Mily RSU Common Stock, $0.10 par value Grant Aquire A 0 10,738 0 10,738
31 Mar 20 Grobstein Michael Deferred Share Units Common Stock, $0.10 par value Grant Aquire A 55.74 313.958 17.5K 87,133.047
31 Mar 20 Emmens Matthew Deferred Share Units Common Stock, $0.10 par value Grant Aquire A 55.74 650.341 36.25K 20,895.03
31 Mar 20 Michael W Bonney Deferred Share Units Common Stock, $0.10 par value Grant Aquire A 55.74 413.976 23.08K 4,215.29
31 Mar 20 Bertolini Robert J Deferred Share Units Common Stock, $0.10 par value Grant Aquire A 55.74 627.915 35K 20,635.524
78.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2152 1790 +20.2%
Opened positions 458 152 +201.3%
Closed positions 96 106 -9.4%
Increased positions 1185 705 +68.1%
Reduced positions 377 686 -45.0%
13F shares
Current Prev Q Change
Total value 1.12T 539.88B +107.5%
Total shares 1.77B 1.35B +30.9%
Total puts 64.67M 29.82M +116.9%
Total calls 24.9M 30.06M -17.1%
Total put/call ratio 2.6 1.0 +161.8%
Largest owners
Shares Value Change
Vanguard 194.86M $12.51B +45.0%
BLK BlackRock 171.34M $11B +38.2%
STT State Street 99.83M $6.41B +45.5%
Wellington Management 83.47M $5.36B -23.9%
FMR 72.42M $4.65B +44.0%
Renaissance Technologies 60.21M $3.86B +83.8%
JPM JPMorgan Chase & Co. 51.49M $3.3B +44.6%
Dodge & Cox 50.27M $3.23B -0.4%
Geode Capital Management 38.44M $2.46B +40.2%
AMP Ameriprise Financial 33.17M $2.13B +6.1%
Largest transactions
Shares Bought/sold Change
Vanguard 194.86M +60.43M +45.0%
BLK BlackRock 171.34M +47.33M +38.2%
STT State Street 99.83M +31.22M +45.5%
Renaissance Technologies 60.21M +27.45M +83.8%
Norges Bank 27.06M +27.06M NEW
Wellington Management 83.47M -26.19M -23.9%
FMR 72.42M +22.13M +44.0%
JPM JPMorgan Chase & Co. 51.49M +15.87M +44.6%
BAC Bank of America 28.01M +14.59M +108.7%
Nuveen Asset Management 21.31M +11.33M +113.5%

Financial report summary

  • We may encounter difficulties integrating ours and Celgene's businesses and operations and, therefore, may not fully realize the projected benefits from our acquisition of Celgene, and our significant additional indebtedness that we incurred and our issuance of additional shares in connection with the acquisition could have negative consequences.
  • The public announcement of data from our clinical studies, or those of our competitors, or news of any developments related to our, or our competitors', products or late-stage compounds may cause significant volatility in our stock price and depending on the data, may result in an adverse impact on our business, financial condition or results of operations. If the development of any of our key late-stage product candidates is delayed or discontinued or a clinical study does not meet one or more of its primary endpoints, our stock price could decline significantly and there may be an adverse impact on our business, financial condition or results of operations.
  • Increased pricing pressure and other restrictions in the U.S. and abroad from MCOs, institutional purchasers and government agencies and programs, among others, continue to negatively affect our revenues and profit margins.
  • We may experience difficulties or delays in the development and commercialization of new products.
  • We could lose market exclusivity of a product earlier than expected.
  • We face intense competition from other manufacturers.
  • Litigation claiming infringement of intellectual property may adversely affect our future revenues and operating earnings.
  • Adverse outcomes in other legal matters could negatively affect our business.
  • We are subject to a variety of U.S. and international laws and regulations.
  • Changes to tax regulations could negatively impact our earnings.
  • Third-party royalties represent a significant percentage of our pretax income and operating cash flow.
  • The failure of third parties to meet their contractual, regulatory and other obligations could adversely affect our business.
  • Failure to execute our business strategy could adversely impact our growth and profitability.
  • Failure to attract and retain highly qualified workforce could affect our ability to successfully develop and commercialize products.
  • Failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions could adversely impact our future results. In addition, any businesses or assets that we acquire in the future may underperform, we may not be able to successfully integrate them into our existing business and the occurrence of a number of unexpected factors could prevent or substantially delay the consummation of an anticipated acquisition, divestiture or merger.
  • We depend on several key products for most of our revenues, cash flows and earnings.
  • We could experience difficulties, delays and disruptions in the manufacturing, distribution and sale of our products.
  • Product labeling changes for our marketed products could result in a negative impact on revenues and profit margins.
  • The illegal distribution and sale by third parties of counterfeit or unregistered versions of our products or stolen products could have a negative impact on our revenues, earnings, reputation and business.
  • We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.
  • Adverse changes in U.S. and global economic and political conditions could adversely affect our profitability.
  • There can be no guarantee that we will pay dividends or repurchase stock.
  • Increased use of social media platforms present risks and challenges.
  • In addition to the risks relating to our common stock, holders of our CVRs and the Celgene CVRs are subject to additional risks.
Content analysis ?
H.S. freshman Avg
New words: AB, Abraxane, Acceleron, accuracy, acid, acknowledged, ACS, adalimumab, Adam, adjudication, advisory, Aetna, AHR, alan, albumin, alive, alter, Alvogen, Alzheimer, AMPLE, Anagni, analog, anemia, Annex, answer, anticancer, anticompetitive, antigen, antiplatelet, appointed, apremilast, arduini, aspirin, asterisk, Aurobindo, Aurolife, automatic, avoidance, azacitidine, Azar, backup, Baran, BCMA, behavior, bempegaldesleukin, bio, blend, blinded, bluebird, BNP, bonney, Bothell, Breakthrough, Breckenridge, broadly, Brook, built, Canadian, capped, CAR, Cardiology, Catalent, cellular, CELMoD, CEO, cereblon, characterized, Chase, chimeric, chose, Cipla, Citibank, cliff, collar, Columbia, column, comment, Commonwealth, compensatory, complication, concomitantly, conference, congressional, converted, Convertible, converting, County, coupled, coupling, CRNM, custody, cutoff, CVR, daily, Dana, david, deal, Debenture, declaratory, Deferral, deoxyribonucleic, departure, detract, Deutsche, diffuse, diligent, dinesh, display, DLBC, DLBCL, Dohme, doublet, Dr, DRL, DTC, DubowSenior, duly, easement, Eid, Eleventh, embed, encumbrance, engineering, enriched, enrichment, EPd, Equiniti, erythroid, ESCC, escrow, esophageal, Eugia, Evercore, exhausted, Farber, featured, fedratinib, fifty, FL, follicular, forfeiture, forma, formatted, Francisco, FTC, FZE, gave, gemoab, gerald, Gerold, GmbH, GvHD, haller, hampered, Hawaii, HBT, hematologic, hematological, hematology, hematopoietic, heparin, herewith, Hetero, Hirawat, holder, House, HRSA, hypermethylation, identification, IDHIFA, Ikena, immunomodulatory, Imnovid, Importantly, indenture, indirect, indolent, inherited, Inline, Inrebic, insignificant, Inspector, intentionally, interfere, interval, italicized, JNDA, JPMorgan, Jr, julia, Juno, karen, Kettering, Kingdom, Kite, knowingly, Labour, lacy, Language, leasehold, legacy, lengthen, lisocabtagene, LMWH, Logistical, longest, Luxembourg, lymphocytic, lymphoma, maker, Manhattan, maraleucel, mathematical, matthew, MDS, mechanistic, Medarex, mediastinal, Mellon, men, michael, Minister, Ministry, misrepresentation, morale, Mutant, mutationally, myelodysplastic, nab, Natco, nationwide, negligent, neutropenia, noncash, nonperformance, nonvalvular, Notably, notification, Notwithstanding, novo, nucleoside, numerically, OAC, ODAC, OfficerMember, omitted, opportunity, opposed, optimistic, Orlando, OS, Otezla, overarching, overcharged, overcome, ozanimod, paclitaxel, page, paliwal, PBM, PCI, pd, penalty, perception, peter, Pike, Pine, placement, plaintiff, plc, polymorphic, Pomalyst, poster, presence, pro, proceed, proportion, punitive, purified, purport, pyrimidine, QoL, Racketeer, radiation, RBC, Rebloyzl, reblozyl, red, Reddy, reengineer, reengineered, referenced, refile, refused, refusing, Regenerative, rejected, relationship, repeal, resale, Rheumatology, ring, ringed, rituximab, Royal, RRMM, RSU, running, Rupert, salesforce, Sam, Samit, Saratoga, sato, scheme, science, Scotland, sector, seropositive, Sharp, shorten, shown, situation, sJNDA, SKI, slight, Sloan, solution, space, SPARC, SPC, Specimen, storch, strike, subordinated, Suisse, Summit, Sun, symptom, syndrome, syringe, tailored, Taisho, Team, temozolomide, Teva, TGA, thalassemia, thalidomide, Thalomid, theodore, thereto, thereunto, thirteen, threatened, thrombocythemia, thrombocytopenia, treble, trend, trustee, unanticipated, unclear, unconstitutional, undersigned, undeveloped, undiagnosed, unenforceable, unexercised, unfair, unjust, unjustified, unjustly, unknown, unlawful, unrelated, unvested, unwind, unwinding, upper, USA, Vehicle, vera, Vessey, vicki, Vidaza, vivo, VKA, voucher, vousden, Washington, wholly, wild, willfully, window, women, XBRL, xi, yale, Yescarta, Zofingen
Removed: agile, annualized, antiretroviral, approximated, asunaprevir, atazanavir, autoimmune, beclabuvir, Brazil, breadth, Chinese, cobicistat, cold, Commentary, complementary, concentrated, consultation, creating, daclatasvir, Dafalgan, Daklinza, decompensated, dedicated, deduction, defend, depth, destructive, disgorgement, diversified, duty, efavirenz, Efferalgan, ehf, essential, exclusively, exercising, FCPA, Fervex, flu, generating, hearing, hold, immunoscience, Indiana, infringe, IRS, liquidation, locally, markup, MF, motor, Mount, mUC, multiplied, mutation, nitroxyl, Ohio, organ, organized, PAD, Padlock, predetermined, prepaid, prodrug, Promedior, promised, protease, PTC, ratio, Reckitt, recognizing, rental, replication, retrospectively, SCLC, screen, selective, sensitive, simplified, siRNA, Sublease, substantive, Sunvepra, syndicate, transcriptase, Truvada, turnover, Tybost, typical, unnamed, utility, validated, variation, Vernon, warrant, West